Patients On Pfizer’s initiative to return clinical trial data to pati... Among the most common reasons for dropping out, patients cite a lack of communication about the trial
R&D Focus on the positive to stop public perception being a barr... Public misconceptions surrounding the process, its risks and its benefits remain a significant barrier to clinical trial participation, which is not surprising in a world where the only int
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
